BioMarin Pharmaceutical traded at $84.84 this Friday September 23rd, decreasing $0.08 or 0.09 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical lost 8.68 percent. Over the last 12 months, its price rose by 7.94 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 85.60 by the end of this quarter and at 78.22 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
84.84
Daily Change
-0.09%
Yearly
7.94%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 16.75 -0.24 -1.41% -1.12%
Acorda Therapeutics 0.29 -0.04 -13.30% -93.96%
Agios Pharmaceuticals 28.99 -0.63 -2.13% -38.99%
Alnylam Pharmaceuticals 200.78 -1.93 -0.95% 7.14%
Amgen 226.97 -0.78 -0.34% 6.25%
Bayer 49.58 -1.93 -3.74% 6.62%
Biogen 197.78 -2.84 -1.42% -32.20%
Bluebird Bio 5.62 -0.35 -5.86% -69.52%
BioMarin Pharmaceutical 84.84 -0.08 -0.09% 7.94%
Gilead Sciences 62.86 -0.91 -1.43% -11.70%
Intercept Pharmaceuticals 15.24 0 0% -5.11%
Incyte Corp 66.89 -0.52 -0.77% -3.06%
Insmed 21.54 -0.63 -2.84% -20.25%
Ionis Pharmaceuticals 43.23 -1.74 -3.87% 19.42%
Moderna Inc 123.64 -0.68 -0.55% -71.26%
Neurocrine Biosciences 103.50 0.16 0.15% 8.96%
Puma Biotechnology 2.35 -0.11 -4.47% -65.54%
PTC Therapeutics 49.16 -0.89 -1.78% 25.12%
Ultragenyx Pharmaceutical 41.50 -1.64 -3.80% -56.37%
Regeneron Pharmaceuticals 697.33 9.07 1.32% 9.15%
Roche Holding 309.30 -2.30 -0.74% -9.14%
Seattle Genetics 139.20 -1.35 -0.96% -13.72%
Sangamo BioSciences 4.95 -0.09 -1.79% -48.44%
Sanofi 38.40 -0.73 -1.87% -19.90%
Sarepta Therapeutics 108.19 -2.68 -2.42% 19.45%
United Therapeutics 207.62 -0.36 -0.17% 6.42%
Vertex Pharmaceuticals 283.45 -2.89 -1.01% 54.38%

Indexes Price Day Year
USND 10868 -198.88 -1.80% -27.78%

BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.